Insmed (INSM) Shares Outstanding (2010 - 2026)
Insmed (INSM) posted quarterly Shares Outstanding (Entity) of $216.5 million for Q1 2026, up 19.03% year-over-year from $181.9 million in Q1 2025, and up 1.06% quarter-over-quarter from $214.3 million in Q4 2025.
Insmed (INSM) Shares Outstanding (2010 - 2026) Analysis & Trends
Insmed's Shares Outstanding (Entity) history runs 17 years deep, the most recent figure standing at $216.5 million for Q1 2026.
- In Q1 2026, Shares Outstanding (Entity) rose 19.03% year-over-year to $216.5 million; the TTM figure through Mar 2026 stood at $216.5 million (up 19.03% YoY), while the FY2025 annual figure was $214.3 million, up 19.44% from the prior year.
- Shares Outstanding (Entity) for Q1 2026 stood at $216.5 million, up from $214.3 million in the prior quarter.
- The five-year high for Shares Outstanding (Entity) was $216.5 million in Q1 2026, with the low at $119.3 million in Q1 2022.
- The 5-year median for Shares Outstanding (Entity) is $148.6 million (2024), against an average of $163.3 million.
- The sharpest annual moves came in 2022 and 2025: Shares Outstanding (Entity) increased 2.85% in 2022, then rose 26.67% in 2025.
- Insmed's Shares Outstanding (Entity) stood at $135.7 million in 2022, then climbed by 9.08% to $148.0 million in 2023, then grew by 21.22% to $179.4 million in 2024, then advanced by 19.44% to $214.3 million in 2025, then grew by 1.06% to $216.5 million in 2026.
- Business Quant data shows INSM's Shares Outstanding (Entity) at $216.5 million in Q1 2026, $214.3 million in Q4 2025, and $212.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares Outstanding (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 253.70 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 102.80 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 62.19 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 210.89 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.45 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 25.05 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 445.06 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 133.61 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 217.35 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | 720.78 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 217.35 Mn |
| Mar 31, 2026 | 215.47 Mn |
| Dec 31, 2025 | 199.01 Mn |
| Sep 30, 2025 | 211.76 Mn |
| Jun 30, 2025 | 189.30 Mn |
| Mar 31, 2025 | 180.86 Mn |
| Dec 31, 2024 | 164.04 Mn |
| Sep 30, 2024 | 173.72 Mn |
| Jun 30, 2024 | 154.70 Mn |
| Mar 31, 2024 | 148.46 Mn |
| Dec 31, 2023 | 140.43 Mn |
| Sep 30, 2023 | 142.90 Mn |
| Jun 30, 2023 | 137.55 Mn |
| Mar 31, 2023 | 136.36 Mn |
| Dec 31, 2022 | 123.04 Mn |
| Sep 30, 2022 | 120.79 Mn |
| Jun 30, 2022 | 119.60 Mn |
| Mar 31, 2022 | 118.93 Mn |
| Dec 31, 2021 | 112.11 Mn |
| Sep 30, 2021 | 117.09 Mn |